Akero Therapeutics, Inc.
AKRO
Peringkat dalam Saham
#3738
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Harga Saham
$54.65
Terakhir disinkronkan: 2025-12-09
Kapitalisasi Pasar
$4.50B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
1.37%
Negara
US
Perdagangan Akero Therapeutics, Inc. (AKRO)
Kategori
Healthcare
Riwayat pemecahan saham untuk Akero Therapeutics, Inc. (AKRO)
Saham Akero Therapeutics, Inc. (simbol: AKRO) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Oct 20, 2026.
Satu lembar saham AKRO yang dibeli sebelum Oct 20, 2026 sekarang setara dengan 0 lembar saham AKRO.
Pemecahan saham terbaru terjadi pada Oct 20, 2026.
Satu lembar saham AKRO yang dibeli sebelum Oct 20, 2026 sekarang setara dengan 0 lembar saham AKRO.
Daftar pemecahan saham
| Tahun | Pemecahan | Kelipatan | Kelipatan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | |||
Pemecahan saham untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pemecahan saham | Kelipatan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|